triggering receptor expressed on myeloid cells like 3, pseudogeneGenealiases: []
Q-omics provides the consensus-scored TREML3P profile across patient tissues and cancer cell-line models. TREML3P expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TREML3P is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TREML3P RNA expression shows 12,988 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where TREML3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TREML3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TREML3P survival associations across molecular data types. TREML3P RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TREML3P RNA expression–survival associations across cancer types. High TREML3P expression shows unfavorable associations in KIRC, STAD, LIHC, HNSC, KIRP and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TREML3P RNA expression.
This table summarizes TREML3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TREML3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TREML3P shows higher tumor expression in HNSC, KIRC, THCA, COAD, LIHC and KIRP. The HNSC box plot shows higher TREML3P RNA expression in tumor versus normal tissue (log2 FC = +1.121, t-test p < 0.001).
This table shows molecular features associated with TREML3P in patient tissues and cancer cell lines. In patient samples, TREML3P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TREML3P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
